Bicara Therapeutics Inc (BCAX) Hedge Fund Ownership (Q2 2026)

Q: Is it too late to buy Bicara Therapeutics Inc (BCAX) following the 2026 Q2 hedge fund 13F filings?

As of today, BCAX has moved -6.8% since the 2026 Q2 13F filing date (August 14, 2026), compared to -31.4% for the XLV sector ETF — an outperformance of +24.6%. Since the quarter end (June 30, 2026), BCAX gained -23.7% vs -23.8% for XLV. The stock has meaningfully outrun its sector. The trade has partially played out; entry is at a premium to the fund's implied reference.

Bicara Therapeutics Inc (BCAX)

168 + Investors. Track Smart Money conviction in BCAX. See who's accumulating, reducing, or initiating positions.

Smart Money Signals — BCAX

Based on 174 hedge funds · latest filing: 2026 Q2 · updated quarterly

📈

Buying streak — 8 quarters in a row

last 6Q

For 8 consecutive quarters, more hedge funds added BCAX than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

🏔️

At the ownership peak (100% of max)

100% of all-time peak

174 hedge funds hold BCAX right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.

🚀

Fast accumulation — +66% more funds vs a year ago

fund count last 6Q

+69 new funds entered over the past year (+66% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.

🟢

More buyers than sellers — 67% buying

111 buying54 selling

Last quarter: 111 funds were net buyers (41 opened a brand new position + 70 added to an existing one). Only 54 were sellers (41 trimmed + 13 sold completely). A clear majority buying is a strong confirmation signal.

📈

More new buyers each quarter (+11 vs last Q)

new funds entering per quarter

Funds opening a new BCAX position: 25 → 43 → 30 → 41. A growing influx of new institutional buyers means the asset is still gathering momentum — the consensus hasn't fully saturated yet.

🔄

Mostly new holders — 43% entered in last year

■ 6% conviction (2yr+) ■ 51% medium ■ 43% new

Only 11 funds (6%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.

💰

Value +56% but shares only +5% — price-driven

Value

+56%

+4%

Last quarter: the total dollar value of institutional holdings rose +56%, but actual share count only changed +5%. The gap is explained by the stock's price rising — not new buying. Strong value growth with weak share growth means the rally is price momentum, not fresh institutional demand.

➡️

Steady discovery — ~41 new funds/quarter

34 → 25 → 43 → 30 → 41 new funds/Q

New funds entering each quarter: 25 → 43 → 30 → 41. Consistent flow of new institutional buyers without clear acceleration or slowdown.

📊

Mixed cohorts — 7% veterans, 53% new entrants

■ 7% veterans ■ 40% 1-2yr ■ 53% new

Of 178 current holders: 12 (7%) held 2+ years, 72 held 1–2 years, 94 (53%) entered in the past year. Balanced distribution — some institutional memory, some recent momentum buyers.

✅

Strong quality — 29% AUM from major funds

29% from top-100 AUM funds

48 of 170 holders rank in the top 100 by AUM, accounting for 29% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

4.8

out of 10

Moderate Exit Risk

Exit risk score 4.8/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Metric	All 13F Filers (2026 Q2)	Prior (2026 Q1)	Change
Funds Holding	168	146	15.07%
13F Shares	72M	70M	2.87%
Total Value	$1.89B	$1.23B	53.16%
New Positions	41	30	+11
Increased Positions	65	57	+8
Closed Positions	15	22	-7
Reduced Positions	41	40	+1
Total Calls	3	3	-
Total Puts	5	4	25.0%
PUT/CALL Ratio	1.67	1.33	Bearish

Metric

All 13F Filers (2026 Q2)

Prior (2026 Q1)

Change

Funds Holding

168

146

15.07%

13F Shares

72M

70M

2.87%

Total Value

$1.89B

$1.23B

53.16%

New Positions

+11

Increased Positions

Closed Positions

-7

Reduced Positions

Total Calls

Total Puts

25.0%

PUT/CALL Ratio

1.67

1.33

Bearish

Institutional Holders (2026 Q2)

168 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in BCAX. Verified SEC 13F-HR filings.

QUARTER:

FILTER:All New Added To Reduced No Change | Overweight >5%

Top 25 BCAX holders by conviction (% of portfolio weight) — 2026 Q2 · Source: SEC Form 13F
#	Investor	% of Portfolio	Shares	Mkt Value
1	Red Tree Management, LLC	63.77%	3,163,517	$93.9M
2	Omega Fund Management, LLC	29.14%	1,822,150	$54.1M
3	Royalty Pharma Sub-Manager, LLC	25.05%	2,388,150	$60.6M
4	Jones Hill Capital LP	5.63%	892,621	$26.5M
5	Acorn Capital Advisors, LLC	5.21%	643,381	$19.1M
6	Vestal Point Capital, LP	3.64%	5,250,000	$155.9M
7	Aisling Capital Management LP	3.58%	568,919	$16.9M
8	Siren, L.L.C.	3.37%	5,602,970	$166.4M
9	Palo Alto Investors LP	2.26%	550,408	$16.3M
10	Ra Capital Management, L.P.	1.87%	7,255,993	$215.4M
11	Tpg GP A, LLC	1.79%	3,010,425	$89.4M
12	Deep Track Capital, LP	1.77%	4,100,000	$121.7M
13	DAFNA Capital Management LLC	1.61%	284,955	$8.5M
14	NAN FUNG TRINITY (HK) Ltd	1.25%	427,885	$12.7M
15	Atle Fund Management AB	1.16%	145,657	$4.3M
16	Napean Trading & Investment Co (Singapore) PTE Ltd	1.16%	113,780	$3.4M
17	Rock Springs Capital Management LP	0.78%	535,286	$15.9M
18	Optimize Financial INC.	0.26%	23,913	$710K
19	Rhenman & Partners Asset Management AB	0.25%	88,150	$2.6M
20	Sound Capital Solutions LLC	0.17%	23,913	$710K
21	Shay Capital LLC	0.13%	68,000	$2.0M
22	VARCOV Co.	0.11%	10,099	$300K
23	Orbimed Advisors LLC	0.11%	191,100	$5.7M
24	Virtus Investment Advisers, LLC	0.10%	15,086	$448K
25	Algert Global LLC	0.08%	233,232	$6.9M

Investor	Ownership History	% of Portfolio	Prev %	Rank	Conviction	Avg Buy Price	13F Score™ 3Y / 7Y	Sell Timing	Shares	Mkt Value	Change	Change %	Source	Quarter	Filed

Frequently Asked Questions — Bicara Therapeutics Inc (BCAX)

What does the Smart Money Trend signal show for BCAX?

Buying streak — 8 quarters in a row: For 8 consecutive quarters, more hedge funds added BCAX than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for BCAX?

More buyers than sellers — 67% buying: Last quarter: 111 funds were net buyers (41 opened a brand new position + 70 added to an existing one). Only 54 were sellers (41 trimmed + 13 sold completely). A clear majority buying is a strong confirmation signal.

What is the fund quality score for BCAX holders?

Strong quality — 29% AUM from major funds: 48 of 170 holders rank in the top 100 by AUM, accounting for 29% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held BCAX?

Mostly new holders — 43% entered in last year: Only 11 funds (6%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.

Is it too late to buy Bicara Therapeutics Inc (BCAX) following the 2026 Q2 hedge fund 13F filings?

As of today, BCAX has moved -6.8% since the 2026 Q2 13F filing date (August 14, 2026), compared to -31.4% for the XLV sector ETF — an outperformance of +24.6%. Since the quarter end (June 30, 2026), BCAX has gained -23.7% vs -23.8% for XLV. The stock has meaningfully outrun its sector. The trade has partially played out; entry is at a premium to the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Market Cap	--
Enterprise Value	--
Trailing P/E	--
Forward P/E	--
PEG Ratio (5yr expected)	--
Price/Sales (ttm)	--
Price/Book (mrq)	--
Enterprise Value/Revenue	--
Enterprise Value/EBITDA	--
Beta (5Y Monthly)	--
Short Ratio (Days to Cover)	--
Short % of Float	--

Profit Margin	--
Return on Assets (ttm)	--
Return on Equity (ttm)	--

Revenue (ttm)	--
Net Income Avi to Common (ttm)	--
Diluted EPS (ttm)	--
Total Cash (mrq)	--
Total Debt/Equity (mrq)	--
Levered Free Cash Flow (ttm)	--

Bicara Therapeutics Inc (BCAX)

Smart Money Signals — BCAX

Buying streak — 8 quarters in a row

At the ownership peak (100% of max)

Fast accumulation — +66% more funds vs a year ago

More buyers than sellers — 67% buying

More new buyers each quarter (+11 vs last Q)

Mostly new holders — 43% entered in last year

Value +56% but shares only +5% — price-driven

Steady discovery — ~41 new funds/quarter

Mixed cohorts — 7% veterans, 53% new entrants

Strong quality — 29% AUM from major funds

Institutional Sentiment Summary — BCAX

Hedge Fund Ownership: BCAX

Market Analysis: BCAX

Analyst Price Targets

Analyst Recommendations

Stock Performance

Company Profile: BCAX

Is It Too Late to Buy Bicara Therapeutics Inc (BCAX) Based on Hedge Fund 13F Filings?

Hedge Fund Positioning: BCAX

Statistics: BCAX

Valuation Measures Data as of: --

Financial Highlights

Institutional Holders (2026 Q2)

Frequently Asked Questions — Bicara Therapeutics Inc (BCAX)

Welcome to 13Foresight!